{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:30:42Z","timestamp":1769689842005,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,7]]},"DOI":"10.7759\/cureus.9057","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T06:07:20Z","timestamp":1594188440000},"source":"Crossref","is-referenced-by-count":5,"title":["Biologic Therapies in Sarcoidosis and Uveitis: A Review"],"prefix":"10.7759","author":[{"given":"Olisaemeka D","family":"Ogbue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parul","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Akku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ThulasiPriya","family":"Jayaprakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1162","article-title":"Efficacy and tolerance of anti-tumor necrosis factor \u03b1 agents in cutaneous sarcoidosis: a French study of 46 cases","volume":"153","author":"Heidelberger V","year":"2017","unstructured":"Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al.. Efficacy and tolerance of anti-tumor necrosis factor \u03b1 agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017, 153:681-685. 10.1001\/jamadermatol.2017.1162","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200007000-00016","article-title":"Bone sarcoidosis","volume":"12","author":"Wilcox A","year":"2000","unstructured":"Wilcox A, Bharadwaj P, Sharma O. Bone sarcoidosis. Curr Opin Rheumatol. 2000, 12:321-330. 10.1097\/00002281-200007000-00016","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.004","article-title":"Clinical characteristics of patients with bone sarcoidosis","volume":"47","author":"Zhou Y","year":"2017","unstructured":"Zhou Y, Lower EE, Li H, Farhey Y, Baughman RP. Clinical characteristics of patients with bone sarcoidosis. Semin Arthritis Rheum. 2017, 47:143-148. 10.1016\/j.semarthrit.2017.02.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000743","article-title":"Neurosarcoidosis: longitudinal experience in a single-center, academic healthcare system","volume":"7","author":"Lord J","year":"2020","unstructured":"Lord J, Paz Soldan MM, Galli J, et al.. Neurosarcoidosis: longitudinal experience in a single-center, academic healthcare system. Neurol NeuroimmunolNeuroinflamm. 2020, 7:743. 10.1212\/NXI.0000000000000743","journal-title":"Neurol NeuroimmunolNeuroinflamm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S94188","article-title":"Profile of adalimumab and it's potential in the treatment of uveitis","volume":"10","author":"Balevic SJ","year":"2016","unstructured":"Balevic SJ, Rabinovich CE. Profile of adalimumab and it's potential in the treatment of uveitis. Drug Des Devel Ther. 2016, 10:2997-3003. 10.2147\/DDDT.S94188","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz DC","year":"2004","unstructured":"Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004, 111:491-500. 10.1016\/j.ophtha.2003.06.014","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12808","article-title":"Infliximab therapy balances regulatory T cells, tumor necrosis factor receptor 2 (TNFR2) expression, and soluble TNFR2 in sarcoidosis","volume":"185","author":"Verwoerd A","year":"2016","unstructured":"Verwoerd A, Hijdra D, Vorselaars AD,  Crommelin HA, van Moorsel CHM, Grutters JC, Claessen AME. Infliximab therapy balances regulatory T cells, tumor necrosis factor receptor 2 (TNFR2) expression, and soluble TNFR2 in sarcoidosis. Clin Exp Immunol. 2016, 185:263-70. 10.1111\/cei.12808","journal-title":"Clin Exp Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/286857","article-title":"Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis","volume":"2013","author":"S\u00e1nchez-Cano D","year":"2013","unstructured":"S\u00e1nchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, R\u00edos-Fern\u00e1ndez R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013, 2013:286857. 10.1155\/2013\/286857","journal-title":"Mediators Inflamm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"Hostettler KE","year":"2012","unstructured":"Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012, 83:218-24. 10.1159\/000328738","journal-title":"Respiration"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs DA","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, et al.. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000, 130:492-513. 10.1016\/s0002-9394(00)00659-0","journal-title":"Am J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00104","article-title":"Anti-TNF drugs for chronic uveitis in adults\u2014a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Leal I","year":"2019","unstructured":"Leal I, Rodrigues FB, Sousa DC, et al.. Anti-TNF drugs for chronic uveitis in adults\u2014a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2019, 6:104. 10.3389\/fmed.2019.00104","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214","article-title":"Current evidence of anti-tumor necrosis factor \u03b1 treatment efficacy in chronic childhood uveitis: a systematic review and meta-analysis approach of individual drugs","volume":"66","author":"Simonini G","year":"2014","unstructured":"Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor \u03b1 treatment efficacy in chronic childhood uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014, 66:1073-84. 10.1002\/acr.22214","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0333-6","article-title":"Early administration of adalimumab for pediatric uveitis due to Beh\u00e7et's disease","volume":"17","author":"Hiyama T","year":"2019","unstructured":"Hiyama T, Harada Y, Doi T, Kiuchi Y. Early administration of adalimumab for pediatric uveitis due to Beh\u00e7et's disease. Pediatr Rheumatol. 2019, 17:29. 10.1186\/s12969-019-0333-6","journal-title":"Pediatr Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-316","article-title":"Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series","volume":"7","author":"La Torre F","year":"2014","unstructured":"La Torre F, Cattalini M, Teruzzi B, Meini A, Moramarco F, Iannone F. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res Notes. 2014, 7:316. 10.1186\/1756-0500-7-316","journal-title":"BMC Res Notes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.191146","article-title":"Pediatric gastrointestinal sarcoidosis: successful treatment with infliximab","volume":"22","author":"Alawdah L","year":"2016","unstructured":"Alawdah L, Nahari A, Alshahrani D, Fagih M, Ghazi S, Al-Hussaini A. Pediatric gastrointestinal sarcoidosis: successful treatment with infliximab. Saudi J Gastroenterol. 2016, 22:391-395. 10.4103\/1319-3767.191146","journal-title":"Saudi J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.5506","article-title":"Intractable neurosarcoidosis effectively treated with infliximab","volume":"55","author":"Sano H","year":"2016","unstructured":"Sano H, Deguchi I, Fukuoka T, et al.. Intractable neurosarcoidosis effectively treated with infliximab. Intern Med. 2016, 55:811-4. 10.2169\/internalmedicine.55.5506","journal-title":"Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20187624","article-title":"Sarcoidosis secondary to lymphocyte active immunotherapy treated with infliximab","volume":"93","author":"Souza GH","year":"2018","unstructured":"Souza GH, Thien CI, Castro VB, Gripp AC. Sarcoidosis secondary to lymphocyte active immunotherapy treated with infliximab. An Bras Dermatol. 2018, 93:764-765. 10.1590\/abd1806-4841.20187624","journal-title":"An Bras Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0237-5","article-title":"Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept","volume":"14","author":"Marques IB","year":"2014","unstructured":"Marques IB, Giovannoni G, Marta M. Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurol. 2014, 14:237. 10.1186\/s12883-014-0237-5","journal-title":"BMC Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-016-0121-5","article-title":"Sarcoidosis presenting as granulomatous myositis in a 16-year-old adolescent","volume":"14","author":"Orandi AB","year":"2016","unstructured":"Orandi AB, Eutsler E, Ferguson C, White AJ, Kitcharoensakkul M. Sarcoidosis presenting as granulomatous myositis in a 16-year-old adolescent. Pediatr Rheumatol. 2016, 14:59. 10.1186\/s12969-016-0121-5","journal-title":"Pediatr Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_63_17","article-title":"The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucoma","volume":"8","author":"Ku WN","year":"2018","unstructured":"Ku WN, Lin CJ, Tsai YY. The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucoma. Taiwan J Ophthalmol. 2018, 8:164-167. 10.4103\/tjo.tjo_63_17","journal-title":"Taiwan J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-200552","article-title":"Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab","volume":"2013","author":"Dragnev D","year":"2013","unstructured":"Dragnev D, Barr D, Kulshrestha M, Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep. 2013, 2013:2013200552. 10.1136\/bcr-2013-200552","journal-title":"BMJ Case Rep"},{"key":"ref22","article-title":"Adalimumab-responsive refractory sarcoidosis following multiple eyebrow tattoos: a case report","volume":"16","author":"Mirzaei A","year":"2017","unstructured":"Mirzaei A, Joharimoghadam MM, Zabihiyeganeh M. Adalimumab-responsive refractory sarcoidosis following multiple eyebrow tattoos: a case report. Tanaffos. 2017, 16:80-83.","journal-title":"Tanaffos"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0011-9","article-title":"A case series of refractory cutaneous sarcoidosis successfully treated with infliximab","volume":"2","author":"Tuchinda P","year":"2012","unstructured":"Tuchinda P, Bremmer M, Gaspari AA. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther (Heidelb). 2012, 2:11. 10.1007\/s13555-012-0011-9","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/595890","article-title":"Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report","volume":"2013","author":"Moretti D","year":"2013","unstructured":"Moretti D, Cianchi I, Vannucci G, Cimaz R, Simonini G. Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. Case Rep Rheumatol. 2013, 2013:595890. 10.1155\/2013\/595890","journal-title":"Case Rep Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000328796","article-title":"Disfiguring annular sarcoidosis improved by adalimumab","volume":"3","author":"Kaiser CA","year":"2011","unstructured":"Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol. 2011, 3:103-106. 10.1159\/000328796","journal-title":"Case Rep Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ndtplus\/sfr142","article-title":"Infliximab as long-term maintenance in steroid-resistant and recurrent sarcoidosis in a renal transplant with central nervous system involvement","volume":"5","author":"Srivastava S","year":"2012","unstructured":"Srivastava S, Rajakariar R, Ashman N, Raftery M, Brown H, Martin JE. Infliximab as long-term maintenance in steroid-resistant and recurrent sarcoidosis in a renal transplant with central nervous system involvement. Clin Kidney J. 2012, 5:53-55. 10.1093\/ndtplus\/sfr142","journal-title":"Clin Kidney J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.70874","article-title":"Dramatic response to infliximab in refractory neurosarcoidosis","volume":"13","author":"Chintamaneni S","year":"2010","unstructured":"Chintamaneni S, Patel AM, Pegram SB, Patel H, Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol. 2010, 13:207-10. 10.4103\/0972-2327.70874","journal-title":"Ann Indian Acad Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand JM","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ, et al.. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017, 89:2092-2100. 10.1212\/WNL.0000000000004644","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0283-0","article-title":"Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis","volume":"33","author":"McCracken C","year":"2019","unstructured":"McCracken C, Yeh S, Jenkins K, et al.. Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis. Eye (Lond). 2019, 33:629-639. 10.1038\/s41433-018-0283-0","journal-title":"Eye (Lond)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet H","year":"2016","unstructured":"Vallet H, Seve P, Biard L, et al.. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016, 68:1522-1530. 10.1002\/art.39667","journal-title":"Arthritis Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens RJ","year":"2012","unstructured":"Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe's Arch Clin Exp Ophthalmol. 2012, 250:713-720. 10.1007\/s00417-011-1844-0","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal DG","year":"2019","unstructured":"Rosenthal DG, Parwani P, Murray TO, et al.. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019, 8:010952. 10.1161\/JAHA.118.010952","journal-title":"J Am Heart Assoc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry","volume":"40","author":"Zannin ME","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM, et al.. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013, 40:74-79. 10.3899\/jrheum.120583","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini G","year":"2011","unstructured":"Simonini G, Taddio A, Cattalini M, et al.. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011, 63:612-618. 10.1002\/acr.20404","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-16","article-title":"Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-\u03b1 therapy in chronic childhood uveitis","volume":"11","author":"Simonini G","year":"2013","unstructured":"Simonini G, Taddio A, Cattalini M, et al.. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-\u03b1 therapy in chronic childhood uveitis. Pediatr Rheumatol. 2013, 11:16. 10.1186\/1546-0096-11-16","journal-title":"Pediatr Rheumatol"},{"key":"ref36","article-title":"Infliximab for treating sarcoidosis patients, Portuguese experience","volume":"17","author":"Aguiar M","year":"2011","unstructured":"Aguiar M, Mar\u00e7al N, Mendes AC, Bugalho de Almeida A. Infliximab for treating sarcoidosis patients, Portuguese experience. Rev Port Pneumol. 2011, 17:85-93.","journal-title":"Rev Port Pneumol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S44542","article-title":"No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis","volume":"6","author":"Banse C","year":"2013","unstructured":"Banse C, Bisson-Vaivre A, Kozyreff-Meurice M, Vittecoq O, Go\u00ebb V. No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. Int J Gen Med. 2013, 6:605-611. 10.2147\/IJGM.S44542","journal-title":"Int J Gen Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe GJ","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, et al.. Adalimumab in patients with active non-infectious uveitis. N Engl J Med. 2016, 375:932-943. 10.1056\/NEJMoa1509852","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomized, placebo-controlled phase 3 trial","volume":"6736","author":"Nguyen QD","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, et al.. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomized, placebo-controlled phase 3 trial. Lancet. 2016, 6736:1-10. 10.1016\/S0140-6736(16)31339-3","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster CS","year":"2003","unstructured":"Foster CS, Tufail F, Waheed NK, et al.. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003, 121:437-440. 10.1001\/archopht.121.4.437","journal-title":"Arch Ophthalmol"},{"key":"ref41","article-title":"The use of biologic therapies in uveitis","volume":"62","author":"Duica I","year":"2018","unstructured":"Duica I, Voinea LM, Mitulescu C, Istrate S, Coman IC, Ciuluvica R. The use of biologic therapies in uveitis. Rom J Ophthalmol. 2018, 62:105-113.","journal-title":"Rom J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/36320-biologic-therapies-in-sarcoidosis-and-uveitis-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:24Z","timestamp":1707506844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/36320-biologic-therapies-in-sarcoidosis-and-uveitis-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.9057","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}